First two fungemia cases caused by Candida haemulonii var. vulnera in China with emerged antifungal resistance

Candida haemulonii var. vulnera is a rare variant of C. haemulonii, which has been previously reported to cause human infections. Owing to the close kinship between C. haemulonii sensu stricto and C. haemulonii var. vulnera, accurate identification of C. haemulonii var. vulnera relied on DNA sequencing assay targeting, for example, rDNA internal transcribed spacer (ITS) region. In this work, two strains of C. haemulonii var. vulnera were collected from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET). The identification capacity of three matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and VITEK 2 YST ID biochemical methods were evaluated against ITS sequencing. In addition, antifungal susceptibility testing was performed using Sensititre YeastOne. Moreover, we comprehensively screened drug-resistant related genes by whole-genome sequencing. The two strains were not correctly identified to species variant level using MALDI-TOF MS and YST ID cards. Both strains were resistant to amphotericin B (minimum inhibitory concentration [MIC] > 2 μg/ml). Moreover, strain F4564 and F4584 exhibited high MIC to fluconazole (>256 μg/ml) and 5-flucytosine (>64 μg/ml), respectively, which were supposed to result from key amino acid substitutions Y132F and G307A in Erg11p and V58fs and G60K substitutions in Fur1p. The rare species C. haemulonii var. vulnera has emerged in China, and such drug-resistant fungal species that can cause invasive diseases require further close attention.

[1]  R. Zancopé-Oliveira,et al.  The Threat Called Candida haemulonii Species Complex in Rio de Janeiro State, Brazil: Focus on Antifungal Resistance and Virulence Attributes , 2022, Journal of fungi.

[2]  Y. Li,et al.  Persistence of an epidemic cluster of Rhodotorula mucilaginosa in multiple geographic regions in China and the emergence of a 5-flucytosine resistant clone , 2022, Emerging microbes & infections.

[3]  V. F. Gimenes,et al.  Antifungal susceptibility profile of Candida clinical isolates from 22 hospitals of São Paulo State, Brazil , 2021, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[4]  B. Bustamante,et al.  Liver abscess caused by Candida haemulonii var. vulnera. First case report in Peru. , 2021, Revista iberoamericana de micologia.

[5]  D. Perlin,et al.  Efficacy of LAMB against Emerging Azole- and Multidrug-Resistant Candida parapsilosis Isolates in the Galleria mellonella Model , 2020, Journal of fungi.

[6]  Sean X. Zhang,et al.  Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates , 2020, Antimicrobial Agents and Chemotherapy.

[7]  M. Kostrzewa,et al.  First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant Candida parapsilosis Isolates Harboring Y132F and/or Y132F+K143R in Turkey , 2020, Antimicrobial Agents and Chemotherapy.

[8]  Rajesh Kumar Gazara,et al.  First Genome Sequences of Two Multidrug-Resistant Candida haemulonii var. vulnera Isolates From Pediatric Patients With Candidemia , 2020, Frontiers in Microbiology.

[9]  Brendan R. Jackson,et al.  Understanding the Emergence of Multidrug-Resistant Candida: Using Whole-Genome Sequencing to Describe the Population Structure of Candida haemulonii Species Complex , 2020, Frontiers in Genetics.

[10]  Z. Tong,et al.  Molecular mechanisms of azole resistance in Candida tropicalis isolates causing invasive candidiasis in China. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  D. Kelly,et al.  The Evolution of Azole Resistance in Candida albicans Sterol 14α-Demethylase (CYP51) through Incremental Amino Acid Substitutions , 2019, Antimicrobial Agents and Chemotherapy.

[12]  J. Flowers,et al.  Origins and geographic diversification of African rice (Oryza glaberrima) , 2018, bioRxiv.

[13]  Sudhir Kumar,et al.  MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. , 2018, Molecular biology and evolution.

[14]  G. Garcia-Effron,et al.  Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review , 2017, Current Fungal Infection Reports.

[15]  M. Arendrup,et al.  Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment , 2017, The Journal of infectious diseases.

[16]  E. Berkow,et al.  Fluconazole resistance in Candida species: a current perspective , 2017, Infection and drug resistance.

[17]  F. Kong,et al.  Identification and Antifungal Susceptibility Profiles of Candida haemulonii Species Complex Clinical Isolates from a Multicenter Study in China , 2016, Journal of Clinical Microbiology.

[18]  L. Juliano,et al.  Identification of Candida haemulonii Complex Species: Use of ClinProToolsTM to Overcome Limitations of the Bruker BiotyperTM, VITEK MSTM IVD, and VITEK MSTM RUO Databases , 2016, Front. Microbiol..

[19]  F. Rossi,et al.  Candida haemulonii Complex Species, Brazil, January 2010–March 2015 , 2016, Emerging infectious diseases.

[20]  A. Chowdhary,et al.  Candida haemulonii species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses , 2016, Emerging Microbes & Infections.

[21]  A. Chowdhary,et al.  Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method , 2015, Journal of Clinical Microbiology.

[22]  M. Kostrzewa,et al.  Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts , 2012, Journal of Clinical Microbiology.

[23]  M. Ghannoum,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution , 2012, Journal of Clinical Microbiology.

[24]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[25]  M. Dornelas-Ribeiro,et al.  Candida haemulonii complex: species identification and antifungal susceptibility profiles of clinical isolates from Brazil. , 2015, The Journal of antimicrobial chemotherapy.

[26]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[27]  Steven D. Brown,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement , 2008 .